|
|
|
|
Medtronic Arctic Front Cardiac CryoAblation Catheter System: PMA submission for FDA approval complete
Medtronic, Inc.(NYSE: MDT) today announced it has completed Pre-Market Approval (PMA) submission in consideration for U.S. Food and Drug Administration (FDA) approval for the Medtronic Arctic Front Cardiac CryoAblation Catheter System, which is designed...
|
|
|
Medtronic Completes Pre-Market Approval Submission to FDA for Arctic Front Cardiac CryoAblation Catheter System
MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc.(NYSE: MDT) today announced it has completed Pre-Market Approval (PMA) submission in consideration for U.S. Food and Drug Administration (FDA) approval for the Medtronic Arctic Front Cardiac CryoAblation...
|
|
|
Medtronic Completes Pre-Market Approval Submission to FDA for Arctic Front Cardiac CryoAblation Catheter System
Companies mentioned in this article: Medtronic, Inc.MINNEAPOLIS -- (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced it has completed Pre-Market Approval (PMA) submission in consideration for U.S. Food and Drug Administration (FDA) approval...
|
|
|
Atrial Fibrillation Epidemiology: Scientists at University of Illinois, Department of Medicine release new data on atrial fibrillation epidemiology
Today's Medical & Research News Scientists at University of Illinois, Department of Medicine release new data on March 17th, 2010 Printer-Friendly Version City:Oak Lawn State:Illinois Country:United States Inflammation Kidney Disease Nephrology Renal...
|
|
|
Dabigatran Etexilate Shows Greater Reductions Than Warfarin In Stroke In Patients With Atrial Fibrillation Across All Stroke Risk Groups
Data presented at the 59th Annual Scientific Session of the American College of Cardiology have shown greater reductions in stroke in patients with atrial fibrillation (AF) for dabigatran etexilate* compared to the current standard of care, warfarin,...
|
|
|
ACC: Several Atrial Fibrillation Approaches Assessed
MONDAY, March 15 (HealthDay News) -- Both cryoablation and catheter ablation appear to be effective in treating atrial fibrillation, while betrixaban seems to be well-tolerated and safe, according to the results of three studies presented at the Annual...
|
|
|
ACC: Ablation bests a-fib drugs in pilot study--onto bigger CABANAs
ATLANTA--Ablative intervention was more effective than drug therapy for preventing recurrent symptomatic atrial fibrillation, according to the CABANA trial presented Monday during a late breaking clinical trial session during the American College of...
|
|
|
Portola Pharmaceuticals and Merck Announce that Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding Compared to Warfarin in Patients with Atrial Fibrillation
ATLANTA, Ga.Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban,...
|
|
|
Portola Pharmaceuticals and Merck Announce that Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding Compared to Warfarin in Patients with Atrial Fibrillation
ATLANTA-- (BUSINESS WIRE) -- Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor.Results showed that a once-daily dose of...
|
|
|
Medtronic Announces Initial Results Of STOP AF Clinical Trial
Medtronic, Inc.(NYSE: MDT) today announced data from the STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial during late-breaking sessions at the 59th Annual Scientific Session of the American College of Cardiology in...
|
|
|
Portola Pharma, Merck Say Betrixaban Reduces Bleeding In Patients With Atrial Fibrillation
Portola Pharma and Merck have said that a mid-stage clinical trial of heart drug candidate betrixaban, an investigational oral direct Factor Xa inhibitor, showed reduced instances of bleeding in certain patients.A once-daily dose of oral betrixaban that was...
|
|
|
Lenient Heart Rate Control As Effective As Strict Control in Atrial Fibrillation
For patients with atrial fibrillation (AF), lenient heart rate control is as effective as guideline-recommended strict control, according to a study presented Monday at the American College of Cardiology conference.Researchers in the Netherlands...
|
|
|
Medtronic Announces Initial Results of STOP AF Clinical Trial
Medtronic, Inc.announced data from the STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial during latebreaking sessions at the 59th Annual Scientific Session of the American College of Cardiology in Atlanta. The data...
|
|
|
Anticoagulation for Mechanical Heart Valves in Patients with and without Atrial Fibrillation
Baber U et al.At present, vitamin K antagonists are the only approved agents for thromboprophylaxis but are limited because of a narrow therapeutic and requirement for frequent monitoring. Anticoagulation for Mechanical Heart Valves in Patients with and...
|
|
|
Portola Pharmaceuticals And Merck Announce That Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence Of Bleeding Compared To Warfarin In Patients With Atrial Fibrillation
_ Portola Pharmaceuticals And Merck Announce That Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence Of Bleeding Compared To Warfarin In Patients With Atrial Fibrillation.
|
|
|
CABANA: Catheter ablation effectively reduced AF
ATLANTA - Percutaneous left atrial catheter ablation may be more effective at the elimination of atrial fibrillation when compared to anti-arrhythmic therapy, according to new findings presented today.The CABANA pilot study included 60 patients...
|
|
|
Medical Minute 3-12: Magnets Guide Hearts Back Into Rhythm
Millions of Americans an irregular heart beat, or atrial fibrillation.If left untreated, it puts people at an increased risk of blood clots and stroke. Now, magnets can guide doctors into hard-to-reach places. Reporter: Melissa Medalie Email...
|
|
|
RACE II: Lenient heart rate control in AF not inferior to strict control
MedWire News: Less rigorous control of heart rate in patients with permanent atrial fibrillation (AF) appears to be as effective as strict rate control at preventing serious adverse events, including death from all causes, reported investigators from the...
|
|
|
ACC: Lenient rate control for a-fib is noninferior to strict controlchange the guidelines?
ATLANTAContrary to current guidelines, taking a lenient approach to controlling heart rate in patients with atrial fibrillation appears to be just as good as taking a strict approach and poses no greater risk of death or other serious complications,...
|
|
|
Portola Pharmaceuticals and Merck Announce that Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding Compared to Warfarin in Patients with Atrial Fibrillation
Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor.Results showed that a once-daily dose of oral betrixaban, given to...
|
|
|
Portola Pharmaceuticals And Merck Announce That Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence Of Bleeding Compared To Warfarin In Patients With Atrial Fibrillation
Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor.Results showed that a once-daily dose of oral betrixaban, given to...
|
|
|
Portola Pharmaceuticals and Merck Announce that Phase 2 Study Showed Investigational Factor Xa Inhibitor, Betrixaban, Reduced Incidence of Bleeding Compared to Warfarin in Patients with Atrial Fibrillation
ATLANTAPortola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor.Results showed that a once-daily dose of oral betrixaban, given to...
|
|
|
ACC: Plavix+aspirin, for those who cant take warfarin, doesn't increase costs
ATLANTAIn high-risk patients with atrial fibrillation who cant tolerate standard blood thinners, such as warfarin, a combination treatment of aspirin and the more expensive clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis) is clinically effective...
|
|
|
Medtronic Announces Initial Results of STOP AF Clinical Trial
Safety and Effectiveness Trial Evaluated the Arctic Front Cardiac CryoAblation Catheter System for the Treatment of Paroxysmal Atrial Fibrillation MINNEAPOLIS & ATLANTA(BUSINESS WIRE) Medtronic, Inc.(NYSE:MDT) today announced data from...
|
|
|
Medtronic Announces Initial Results of STOP AF Clinical Trial
Medtronic, Inc.(NYSE:MDT) today announced data from the STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial during late-breaking sessions at the 59th Annual Scientific Session of the American College of Cardiology in...
|
